Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) hit a new 52-week high during mid-day trading on Monday following insider buying activity. The stock traded as high as $58.69 and last traded at $58.71, with a volume of 645,889 shares changing hands. The stock had previously closed at $56.39.
Specifically, SVP C Frank Bennett sold 10,000 shares of Ionis Pharmaceuticals stock in a transaction dated Monday, July 24th. The shares were sold at an average price of $59.29, for a total value of $592,900.00. Following the completion of the transaction, the senior vice president now owns 25,041 shares of the company’s stock, valued at approximately $1,484,680.89. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Chairman Stanley T. Crooke sold 16,500 shares of Ionis Pharmaceuticals stock in a transaction dated Monday, July 17th. The shares were sold at an average price of $52.45, for a total transaction of $865,425.00. Following the completion of the transaction, the chairman now directly owns 53,014 shares of the company’s stock, valued at approximately $2,780,584.30. The disclosure for this sale can be found here. In the last three months, insiders sold 54,379 shares of company stock valued at $2,946,052. Insiders own 1.86% of the company’s stock.
Several analysts recently commented on IONS shares. BMO Capital Markets reaffirmed an “outperform” rating and set a $59.00 target price on shares of Ionis Pharmaceuticals in a report on Wednesday, April 26th. Stifel Nicolaus lifted their target price on shares of Ionis Pharmaceuticals from $42.00 to $50.00 and gave the stock a “hold” rating in a report on Wednesday, August 9th. TheStreet raised shares of Ionis Pharmaceuticals from a “d+” rating to a “c-” rating in a report on Wednesday, July 5th. Leerink Swann reaffirmed an “outperform” rating and set a $45.00 target price (down previously from $47.00) on shares of Ionis Pharmaceuticals in a report on Wednesday, May 17th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $64.00 target price on shares of Ionis Pharmaceuticals in a report on Wednesday, July 26th. Three analysts have rated the stock with a sell rating, six have issued a hold rating and seven have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $48.91.
Ionis Pharmaceuticals (NASDAQ:IONS) last issued its earnings results on Tuesday, August 8th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by $0.03. The business had revenue of $104.15 million for the quarter, compared to the consensus estimate of $93.29 million. Ionis Pharmaceuticals had a return on equity of 15.52% and a net margin of 5.25%. Ionis Pharmaceuticals’s revenue for the quarter was up 170.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.47) EPS. On average, analysts expect that Ionis Pharmaceuticals, Inc. will post ($0.20) earnings per share for the current fiscal year.
A number of institutional investors have recently modified their holdings of the company. Parallel Advisors LLC raised its position in shares of Ionis Pharmaceuticals by 62.8% in the second quarter. Parallel Advisors LLC now owns 2,073 shares of the company’s stock worth $109,000 after buying an additional 800 shares in the last quarter. Hanseatic Management Services Inc. purchased a new position in Ionis Pharmaceuticals during the first quarter worth approximately $138,000. Westpac Banking Corp purchased a new position in Ionis Pharmaceuticals during the first quarter worth approximately $171,000. The Manufacturers Life Insurance Company raised its position in Ionis Pharmaceuticals by 9.1% in the second quarter. The Manufacturers Life Insurance Company now owns 3,744 shares of the company’s stock worth $190,000 after buying an additional 311 shares during the period. Finally, WFG Advisors LP raised its position in Ionis Pharmaceuticals by 77.2% in the second quarter. WFG Advisors LP now owns 3,800 shares of the company’s stock worth $193,000 after buying an additional 1,655 shares during the period. Hedge funds and other institutional investors own 89.08% of the company’s stock.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.
What are top analysts saying about Ionis Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Ionis Pharmaceuticals Inc. and related companies.